How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

HealthTech draft guidance

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

Guidance development process

NICE HealthTech guidance evaluates digital technologies, diagnostics and medical devices (including artificial intelligence). It provides evidence-based recommendations about how safe and effective these technologies are, and their cost effectiveness. The guidance supports healthcare professionals and commissioners to ensure that patients get the best possible treatments. NICE aims to promote innovations that meet the needs of patients and the healthcare system.

This guidance has been developed as routine-use HealthTech guidance, for HealthTech products that address a national unmet need in the NHS and may be suitable for widespread use.

Find out more on the NICE webpage on HealthTech guidance.

NICE is producing this guidance on ex-situ machine perfusion devices to preserve deceased donor livers for transplantation in the NHS in England. The medical technologies advisory committee has considered the evidence and the views of clinical and patient experts.

This document has been prepared for consultation with the stakeholders. It summarises the evidence and views that have been considered, and sets out the recommendations made by the committee. NICE invites comments from the stakeholders for this evaluation and the public. This document should be read along with the evidence.

The committee is interested in receiving comments on the following:

  • Has all of the relevant evidence been taken into account?

  • Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

After consultation:

  • Based on the consultation comments received, the committee may meet again.

  • If the committee meets again it will consider the evidence, this evaluation consultation document and comments from stakeholders.

  • The committee will then prepare the final draft guidance, which will go through a resolution process before the final guidance is agreed.

Note that this document is not NICE's final guidance on ex-situ machine perfusion devices to preserve deceased donor livers for transplantation. The recommendations in section 1 may change after consultation.

More details are available in NICE's HealthTech programme manual.

Key dates:

Closing date for comments: 10 June 2026

Second committee meeting: 25 June 2026